Literature DB >> 23318428

Involvement of EphA2-mediated tyrosine phosphorylation of Shp2 in Shp2-regulated activation of extracellular signal-regulated kinase.

K Miura1, Y Wakayama, M Tanino, Y Orba, H Sawa, M Hatakeyama, S Tanaka, H Sabe, N Mochizuki.   

Abstract

Shp2 is a positive regulator for Erk activation downstream of receptor tyrosine kinases for growth factors. It has been controversial how Shp2 induces Erk activation. We here demonstrate that EphA2 is responsible for Shp2-mediated Erk activation by phosphorylating Tyr542 and Tyr580 of Shp2 in the cells stimulated with growth factors. In NMuMG mammary epithelial cells stimulated with hepatocyte growth factor (HGF), HGF-dependent Erk phosphorylation was prolonged only in the presence of EphA2. This Erk activation paralleled the phosphorylation of Tyr542/580 of Shp2 and the association of Grb2 with Shp2, suggesting the positive signal involving Grb2 signal to activate Ras-Erk pathway. Immunohistochemical studies of mammary cancer specimens revealed that the cancer progression was associated with both Tyr580 phosphorylation of Shp2 and increased expression of EphA2, which were also correlated with increased Erk phosphorylation. Overexpression of either Shp2Thr468Met (a phosphatase-defective mutant found in Lentigines, Electrocardiographic abnormalities, Ocular hypertelorism, Pulmonary stenosis, Abnormal genitalia, Retardation of growth and sensorineural Deafness (LEOPARD) syndrome) or Shp2Asn308Asp (a phosphatase-active mutant found in Noonan syndrome) with EphA2 exhibited comparable activation of Erk and stronger activation than wild-type Shp2, suggesting the phosphatase-independent Erk activation. Expression of Shp2Thr468Met with Tyr542/580Phe mutations resulted in the suppression of Erk activation. Phosphatase-active and -inactive, and wild-type Shp2s bound equally to Grb2, suggesting that phosphorylation of Tyr542/580 of Shp2 was essential but not sufficient for Shp2-mediated Erk activation. We found that Gab1 (Grb2-associated binder 1) was involved in the mutant Shp2-mediated Erk activation. Zebrafish injected with Shp2Thr468Met mRNA showed cardiac edema, whereas those depleted of EphA2b showed less phenotype, suggesting that EphA2 might partly account for the phenotype of LEOPARD syndrome. Collectively, tyrosine phosphorylation of Shp2 by EphA2 contributes to the phosphatase-independent Shp2-mediated activation of Erk and might be involved in Shp2-associated diseases.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23318428     DOI: 10.1038/onc.2012.571

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  21 in total

1.  The receptor tyrosine kinase EphA2 promotes glutamine metabolism in tumors by activating the transcriptional coactivators YAP and TAZ.

Authors:  Deanna N Edwards; Verra M Ngwa; Shan Wang; Eileen Shiuan; Dana M Brantley-Sieders; Laura C Kim; Albert B Reynolds; Jin Chen
Journal:  Sci Signal       Date:  2017-12-05       Impact factor: 8.192

Review 2.  Swimming toward solutions: Using fish and frogs as models for understanding RASopathies.

Authors:  Victoria L Patterson; Rebecca D Burdine
Journal:  Birth Defects Res       Date:  2020-06-07       Impact factor: 2.344

3.  The Q510E mutation in Shp2 perturbs heart valve development by increasing cell migration.

Authors:  Michelle A Edwards; Kathryn Crombie; Christine Schramm; Maike Krenz
Journal:  J Appl Physiol (1985)       Date:  2014-10-30

Review 4.  Predicting resistance by selection of signaling pathways.

Authors:  Niki Karachaliou; Rafael Rosell; Miguel Angel Molina; Santiago Viteri
Journal:  Transl Lung Cancer Res       Date:  2014-04

Review 5.  A comprehensive review of SHP2 and its role in cancer.

Authors:  Moges Dessale Asmamaw; Xiao-Jing Shi; Li-Rong Zhang; Hong-Min Liu
Journal:  Cell Oncol (Dordr)       Date:  2022-09-06       Impact factor: 7.051

6.  PTPN11 Plays Oncogenic Roles and Is a Therapeutic Target for BRAF Wild-Type Melanomas.

Authors:  Kristen S Hill; Evan R Roberts; Xue Wang; Ellen Marin; Taeeun D Park; Sorany Son; Yuan Ren; Bin Fang; Sean Yoder; Sungjune Kim; Lixin Wan; Amod A Sarnaik; John M Koomen; Jane L Messina; Jamie K Teer; Youngchul Kim; Jie Wu; Charles E Chalfant; Minjung Kim
Journal:  Mol Cancer Res       Date:  2018-10-24       Impact factor: 5.852

7.  EphA2 Expression Is a Key Driver of Migration and Invasion and a Poor Prognostic Marker in Colorectal Cancer.

Authors:  Philip D Dunne; Sonali Dasgupta; Patrick G Johnston; Sandra Van Schaeybroeck; Jaine K Blayney; Darragh G McArt; Keara L Redmond; Jessica-Anne Weir; Conor A Bradley; Takehiko Sasazuki; Senji Shirasawa; Tingting Wang; Supriya Srivastava; Chee Wee Ong; Ken Arthur; Manuel Salto-Tellez; Richard H Wilson
Journal:  Clin Cancer Res       Date:  2015-08-17       Impact factor: 12.531

8.  PIM1 kinase regulates cell death, tumor growth and chemotherapy response in triple-negative breast cancer.

Authors:  Fara Brasó-Maristany; Simone Filosto; Steven Catchpole; Rebecca Marlow; Jelmar Quist; Erika Francesch-Domenech; Darren A Plumb; Leila Zakka; Patrycja Gazinska; Gianmaria Liccardi; Pascal Meier; Albert Gris-Oliver; Maggie Chon U Cheang; Anna Perdrix-Rosell; Manar Shafat; Elodie Noël; Nirmesh Patel; Kristen McEachern; Maurizio Scaltriti; Pau Castel; Farzana Noor; Richard Buus; Sumi Mathew; Johnathan Watkins; Violeta Serra; Pierfrancesco Marra; Anita Grigoriadis; Andrew N Tutt
Journal:  Nat Med       Date:  2016-10-24       Impact factor: 53.440

Review 9.  Functions of Shp2 in cancer.

Authors:  Jie Zhang; Fei Zhang; Ruifang Niu
Journal:  J Cell Mol Med       Date:  2015-06-19       Impact factor: 5.310

10.  The tyrosine phosphatase SHP-2 dephosphorylated by ALV-J via its Env efficiently promotes ALV-J replication.

Authors:  Tuofan Li; Jing Xie; Xiaohui Yao; Jun Zhang; Chunping Li; Dan Ren; Luyuan Li; Quan Xie; Hongxia Shao; Aijian Qin; Jianqiang Ye
Journal:  Virulence       Date:  2021-12       Impact factor: 5.882

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.